Figure 1
From: Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma
Allovectin anti-tumor efficacy in a murine melanoma model. C57BL/6 mice were implanted subcutaneously on the flank with B16-F10 murine melanoma cells. At 14 days when tumors were palpable (50–300 mm3), animals were randomized to receive either saline (100 μl qdx6) or Allovectin (100 μg in 100 μl qdx2, 4 or 6). Tumor volume was then followed using caliper measurements and plotted vs days post-treatment.
